Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.

ABSTRACT:

Introduction

Androgen deprivation therapy (ADT) is a mainstay of treatment against advanced prostate cancer (PC). As a treatment goal, suppression of plasma testosterone levels to <50 ng/dl has been established over decades. Evidence is growing though that suppression to even lower levels may add further clinical benefit. Therefore, we undertook a pooled retrospective analysis on the efficacy of 1-, 3-, and 6-month sustained-release (SR) formulations of the gonadotropin-releasing hormone (GnRH) agonist triptorelin to suppress serum testosterone concentrations beyond current standards.

Methods

Data of 920 male patients with PC enrolled in 9 prospective studies using testosterone serum concentrations as primary endpoint were pooled. Patients aged 42-96 years had to be eligible

SUBMITTER: Breul J 

PROVIDER: S-EPMC5331090 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature